Cancer-fighting bacteria to begin Phase 2 trials
Israel’s NeoTX Therapeutics (see here Mar 2020) has had FDA approval to begin Phase 2a human trials of its Naptumomab Estafenatox (NAP) treatment for non-small cell lung cancer. NAP binds bacteria to the tumor while activating tumor specific immune cells.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink